Apellis shares plunge after incident in two clinical trials

Apellis Pharmaceuticals Inc.'s share price dropped sharply Thursday after the company disclosed that it had temporarily halted human testing of its signature treatment in two clinical trials. In mid-afternoon trading, Apellis (Nasdaq: APLS) shares were down $3.14, or about 19 percent, at $13.57. The company's shares closed at $16.71 on Wednesday. The Crestwood, Ky.-based biopharmaceutical company, which is conducting late-stage clinical trials of the treatment, disclosed in a Securit ies and Exchange…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news